Tudor Horizon helps early pipeline teams and biotech companies size the opportunity, test the product potential and decide whether to advance, refine or reconsider an asset.
Early pipeline teams often need to make important investment and indication decisions before the product profile is complete. Biotech companies face the same challenge, often with fewer assets and more riding on every decision.
Tudor Horizon starts with a verbal briefing and the product information available today. It provides a structured assessment of the asset’s potential, the patients most likely to benefit and what would strengthen the case for continued investment.
Test potential to change practice, clinical value and the level of meaningful differentiation at launch.
Know whether the asset merits further investment.
Size the suitable, strongest-fit and meaningful-improvement patient pools from HCP workload.
Build a grounded patient pool assumption.
Separate new patient initiation from switching inadequately managed and stable patients.
See where early use would actually come from.
Identify the barriers, profile changes and additional evidence that would strengthen the asset.
Know what to improve before investing further.
The score brings together practice change potential, clinical value, patient opportunity and likely early use. Results can be explored by market and priority patient group, with every recommendation linked back to the underlying evidence.
The evidence supports continued investment in the asset.
Specific product profile changes or additional evidence could strengthen the opportunity.
The current profile is unlikely to support a sufficiently strong future opportunity.
Begin with a verbal briefing and the product information available today. A completed TPP is not needed upfront.
Nimbus© produces the survey within minutes, ready for Tudor specialists to review and finalise the same day.
Access the live dashboard from day three of data collection and receive the final report the day data collection closes.
Nimbus© accelerates the repeatable work. Tudor specialists remain accountable for design, quality, interpretation and the final recommendation.
Horizon asks HCPs to assess the product profile exactly as written, without assuming benefits, evidence or access conditions that are not provided.
Relevant HCP workload grounds the patient opportunity. New patient initiation and switching are measured separately. Barriers, profile changes and evidence needs show what would strengthen the asset.
This provides a more transparent basis for the next investment decision, without implying a level of precision the available evidence cannot support.
Tudor Horizon gives early pipeline teams and biotech companies a faster, structured way to assess an asset before committing further time and investment.
Start with a verbal briefing and the information currently available.